CAR-T治疗R/R DLBCL中FDG-PET标准化解读:DESCAR-T研究
该研究基于法国DESCAR-T注册队列,纳入212例接受商业化抗CD19 CAR-T治疗的R/R DLBCL患者,在输注前及输注后1个月或3个月进行集中审阅的PET/CT,测量TMTV与SUVmax并记录Deauville评分。结果显示基线TMTV截断值30 cm³可显著分层PFS和OS,M1和M3时DS1-3较DS4-5显著改善PFS和OS,DS5预后最差,且无完全代谢缓解者残留TMTV提供额外预后价值。
要点
- 基线TMTV截断值30 cm³可显著分层R/R DLBCL接受CAR-T患者的PFS和OS。
- M1时DS1-3较DS4-5显著改善PFS和OS,DS5患者预后最差。
- 无完全代谢缓解者,残留TMTV提供额外预后价值。
核心结论
- 基线TMTV、DS评估的代谢反应及随访PET/CT残留TMTV是抗CD19 CAR-T治疗R/R DLBCL的强预后生物标志物。
研究设计与样本
- 基于法国DESCAR-T注册队列,纳入212例三线及以上接受商业化抗CD19 CAR-T治疗的R/R DLBCL患者,要求输注前及输注后1个月或3个月有集中审阅的PET/CT。
主要发现
- 基线中位SUVmax为16.4,中位TMTV为41.3 cm³。
- 基线TMTV截断值30 cm³在单变量和多变量分析中均显著分层PFS和OS,LDH亦为独立因素。
- M1时DS1-3较DS4-5显著改善PFS(中位21.8 vs 1.8个月,p<0.0001)和OS(中位未达到 vs 6.3个月,p<0.0001)。
- M1时DS5患者预后最差(PFS中位0.1个月,OS中位4.5个月)。
- M3时DS1-3较DS4-5预后更好,DS5患者预后最差;无完全代谢缓解者残留TMTV提供额外预后价值。
关键数值与推荐
- 基线TMTV截断值30 cm³用于PFS和OS分层。
- M1时DS1-3定义为完全代谢缓解,与DS4-5相比PFS中位21.8 vs 1.8个月(p<0.0001),OS中位未达到 vs 6.3个月(p<0.0001)。
- M1时DS5患者PFS中位0.1个月,OS中位4.5个月。
临床怎么用
- 对接受抗CD19 CAR-T治疗的R/R DLBCL患者,可结合基线TMTV、M1和M3的Deauville评分及残留TMTV进行预后分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CAR T-cell therapy has changed the management of relapsed/refractory (R/R) Diffuse large B-cell lymphoma (DLBCL). Fluorodeoxyglucose Positron Emission Tomography Computed Tomography (PET/CT) plays a central role in lymphoma response assessment, but its prognostic use remains insufficiently standardized in this setting. METHODS: Patients from the French DESCAR-T registry treated in third line or beyond with commercial anti-CD19 CAR T-cells in real-life, and having centrally reviewed PET/CT before infusion, and at one month (M1) or three months (M3) post-infusion were included. For each visit, Total Metabolic Tumor Volume (TMTV) and SUVmax were measured. Deauville score (DS) and response according to 2014 Lugano classification were registered on follow-up PET/CT. Optimal TMTV cut-offs at baseline, M1 and M3 follow-up for progression-free survival (PFS) and overall survival (OS) and the prognostic impact of DS at M1 and M3 were determined. RESULTS: A total of 212 R/R DLBCL patients were analysed. Baseline median SUVmax was 16.4 and median TMTV 41.3 cm3. A baseline TMTV cut-off of 30 cm3 significantly stratified patients for PFS and OS, in both univariate and multivariate analysis, along with LDH. Complete metabolic response (DS 1-3) at M1 was significantly associated with better PFS M1 and OS M1 than DS4-5 (for PFS M1: median of 21.8 vs 1.8 vs months; p < 0.0001; for OS M1: median not reached versus median of 6.3 months; p < 0.0001). DS5 identified patients with the worst outcomes (for PFS M1: median of 0.1 month and for OS M1: median of 4.5 months). Similarly, at M3 DS1-3 was associated with a better outcome than DS4-5, and patients with DS5 had the worst outcome. In patients without complete metabolic response residual TMTV provided additional prognostic value. CONCLUSION: Baseline TMTV and metabolic response assessed by DS, together with residual TMTV on follow-up PET/CT, are strong prognostic biomarkers in R/R DLBCL patients treated with anti-CD19 CAR T-cells.
引用
- Al Tabaa Y, Bailly C, Palard-Novello X, et al. Standardized FDG-PET interpretation during CAR T-cell therapy in R/R DLBCL: a DESCAR-T study. Eur J Nucl Med Mol Imaging. 2026. PMID: 42501071. doi:10.1007/s00259-026-08055-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。